These molecular subtypes play a critical role in determining the prognosis and treatment strategies for BC patients, and specific HER2-directed treatments such as trastuzumab and pertuzumab, are being used as first-line therapies to treat HER2-positive tumors [4, 5]. Here, ERBB2 is linked to breast cancer.